Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

Presently, several small molecule protein degraders are being evaluated {RootsAnalysis}


Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease causing / associated proteins, using bifunctional small molecule drugs. Presently, the most popular and promising class of interventions in this field of research, is proteolysis targeting chimeras (PROTACs); these can simultaneously bind a target protein and an E3-ubiquitin ligase, and thereby, facilitate the selective ubiquitination and eventual proteasome-mediated degradation of the target protein. The most interesting feature of this mechanism of drug action is the fact that PROTACs and other targeted protein degraders can eliminate protein targets regardless of their function.

 

To order this 330+ page report, which features 115+ figures and 180+ tables, please visit this link

 

The USD 3.3 billion (by 2030) financial opportunity within the targeted protein degradation enabling technologies market has been analyzed across the following segments:

§  Type of Payment

§  Upfront Payment

§  Milestone Payment

 

§  Types of Protein Degraders

§  Degronimids

§  PROTACs

§  SARDs / SERDs

§  Specific BET and DUB Inhibitors

§  Other Inhibitors

 

§  Therapeutic Areas

  • Oncological Disorders
  • Neurological Disorders
  • Others

 

§  Route of Administration

§  Oral

§  Intravenous

§  Others

 

§  Key Geographical Regions 

§  North America

§  Europe

§  Asia-Pacific

 

The Targeted Protein Degradation Market, 2021-2030 report features the following companies, which we identified to be key players in this domain:

§  Arvinas

§  AstraZeneca

§  BioTheryX

§  C4 Therapeutics

§  Captor Therapeutics

§  Celgene

§  Genentech

§  Hinova Pharmaceuticals

§  Kangpu Biopharmaceuticals

§  Kymera Therapeutics

§  Mission Therapeutics

§  Progenra

§  Radius Health

§  Sanofi Genzyme

§  Zenopharm

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction
 

1.    Current Market Landscape: Target Protein Degradation-Based Therapeutics
 

5. Current Market Landscape: Target Protein Degradation Enabling Technologies
 

6. Company Profiles
 

7. Clinical Trial Analysis 
 

8. Academic Grants Analysis
 

9. Publication Analysis

 

10. Patent Analysis
 

11. KOL Analysis
 

12. Partnerships and Collaborations
 

13. Funding and Investment Analysis
 

14. Market Sizing and Opportunity Analysis

 

15. Licensing Deal Structure

 

16. Executive Insights

 

17. Concluding Remarks

 

18. Appendix 1: Tabulated Data

 

19. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

 

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...